faricimab Vabysmo
Selected indexed studies
- Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. (Ophthalmology, 2024) [PMID:38158159]
- Faricimab: First Approval. (Drugs, 2022) [PMID:35474059]
- TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. (Ophthalmology, 2024) [PMID:38382813]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Faricimab: First Approval. (2022) pubmed
- Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. (2024) pubmed
- Faricimab. (2006) pubmed
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. (2022) pubmed
- TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. (2024) pubmed
- PMID:38498652 (2023) pubmed
- PMID:38620338 (2022) pubmed
- PMID:38620376 (2022) pubmed
- PMID:38713786 (2022) pubmed
- PMID:40763228 (2025) pubmed